Valuation: Insmed Incorporated

Market Cap 20.74B 18.61B 17.2B 15.58B 29.11B 1,975B 29.46B 206B 81.92B 1,034B 77.82B 76.18B 3,281B P/E 2026 *
-59.2x
P/E 2027 * 126x
Enterprise Value 20.13B 18.06B 16.7B 15.13B 28.26B 1,918B 28.6B 200B 79.54B 1,003B 75.56B 73.96B 3,186B EV / Sales 2026 *
11.1x
EV / Sales 2027 * 6.74x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day+2.13%
1 week+1.37%
Current month-15.03%
1 month-17.69%
3 months-7.40%
6 months-28.68%
Current year-44.28%
1 week 92.62
Extreme 92.625
97.92
1 month 92.62
Extreme 92.625
118.5
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 09/09/2012
Director of Finance/CFO 45 30/01/2020
Chief Tech/Sci/R&D Officer 62 18/12/2019
Director TitleAgeSince
Chairman 75 15/06/2009
Chairman 57 07/11/2018
Director/Board Member 72 28/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
09/09/26 Sell

Director

-25,000 0.0114%
17/08/26 Sell

Director

-5,000 0.0023%
10/08/26 Exercice

Chief Operating Officer

719,550 0.3320%
Change 5-day change 1-year change 3-year change Capi.($)
+2.13%+1.37%-40.87%+306.11% 20.74B
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+2.10%+12.10%+81.21% 54.55B
-0.94%+0.77%+8.85%+100.19% 53.59B
+2.76%+4.18%+28.34%+55.07% 44.75B
+2.00%-2.90%+18.37%+119.04% 41.62B
+1.34%-3.98%+225.44%+914.08% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+48.65%+106.84%+92.73% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.30%-0.45%+42.86%+177.15% 40.12B
Weighted average by Cap. +3.16%-0.31%+42.99%+168.95%

Financials

2026 *2027 *
Net sales 1.81B 1.62B 1.5B 1.36B 2.54B 172B 2.57B 17.93B 7.14B 90.12B 6.79B 6.64B 286B 2.91B 2.61B 2.41B 2.19B 4.08B 277B 4.13B 28.86B 11.49B 145B 10.92B 10.69B 460B
Net income -334M -300M -277M -251M -469M -31.83B -475M -3.32B -1.32B -16.66B -1.25B -1.23B -52.88B 179M 161M 149M 135M 252M 17.08B 255M 1.78B 708M 8.94B 673M 659M 28.37B
Net Debt -603M -541M -500M -453M -847M -57.45B -857M -5.98B -2.38B -30.06B -2.26B -2.22B -95.44B -1.13B -1.02B -941M -853M -1.59B -108B -1.61B -11.26B -4.48B -56.56B -4.26B -4.17B -180B
Projected Income Statement - Annual - Insmed Incorporated
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
28/10/26 US$96.98 +2.13% 4,647,588
27/10/26 US$94.96 +1.75% 3,349,378
26/10/26 US$93.33 -0.06% 3,379,924
23/10/26 US$93.39 -1.76% 3,414,134
22/10/26 US$95.06 +1.08% 3,099,798
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Insmed Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
94.96USD
Average target price
196.14USD
Spread / Average Target
+106.55%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Insmed Incorporated
  1. Stock Market
  2. Stocks
  3. INSM Stock